Seeking Alpha

TRADE ALERT: Sell Unity Software, Case Study In Discipline; 50%+ Return In 7 Months

Back in February, roughly 7 months ago, I recommended Unity to paying subscribers.This was a tough pick to make. In the weeks ahead, the market would have to deal with the onslaught of Liberation ...
Seeking Alpha

UNITY Biotechnology Announces Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients with ...
Nasdaq

UNITY Biotechnology to Present 36-Week Data from ASPIRE Phase 2B Study at ARVO 2025 Annual Meeting

UNITY Biotechnology, Inc. has announced that it will present data from its ASPIRE Phase 2B study on its senolytic candidate, UBX1325, targeting diabetic macular edema at the upcoming ARVO 2025 Annual ...
Nasdaq

UNITY Biotechnology Reports Q1 2025 Financial Results and ASPIRE Study Data on UBX1325 for Diabetic Macular Edema

UNITY Biotechnology, Inc. reported its financial results for the first quarter of 2025, highlighting the 24-week and partial 36-week topline data from its Phase 2b ASPIRE study in diabetic macular ...